Proactis (PHD): Corp
Companies: Proactis Holdings Plc
genedrive (GDR): Corp COVID-19 test PCR test receives CE-IVD mark | Ideagen (IDEA): Corp PleaseReview on the world stage | Proactis (PHD): Corp Positive TCV update
Companies: IDEA PHD GDR
Destiny Pharma (DEST): Corp FY 2019 results – COVID opportunities and implications | Proactis (PHD): Corp Stability shows base for growth
Companies: Proactis Holdings Plc Destiny Pharma Plc
Positive interims for the period detail performance in line with unchanged expectations, and the confrontation of the three themes which had concerned investors: covenant headroom; churn; and growth. The reset of the bank facility was announced yesterday. Churn has been arrested, with retention improved across the business, even with the High Risk Accounts (HRAs). Annual recurring revenue (ARR) gives visibility of £40.7m in core revenue, growing at 7% annualised (excluding HRAs, which typically take a single product, or non-core services) – and the total contract value of deals won (excluding renewals) with new and existing clients achieved an historic high for a six-month period, adding to ARR in subsequent periods. With each concern addressed, the group offers stability for the year to July 2020 – and evidence of the realism of delivering growth into FY21. We reiterate our 80p target price, based on 10x FY21 EV/EBITDA, and look forward to further newsflow.
ANGLE (AGL): Corp Progress report since COVID-19 lockdown | NAHL (NAH): Corp Navigating change in difficult markets | Omega Diagnostics (ODX): Corp VISITECT CD4 supply agreement with CHAI | Proactis (PHD): Corp Reset of banking facility | STM (STM): Corp Transitioning into new markets from a robust base | Universe Group (UNG): Corp Strong FY19 trading update, strong FY20 order book
Companies: ODX PHD STM UNG AGL NAH
NAHL (NAH): Corp | Omega Diagnostics (ODX): Corp | Proactis (PHD): Corp | Wameja (WJA): Corp
Companies: WJA ODX PHD NAH
Allergy Therapeutics (AGY): Corp Interims – progressing to plan, upgrades due to R&D | Oncimmune Holdings (ONC): Corp Biodesix launches EarlyCDT Lung test in the US | PCI Pal (PCIP): Corp Record H1 revenue growth with a caveat on timing | Proactis (PHD): Corp Restoring forecasts after conclusion of FSP
Companies: AGY PHD PCIP ONC
FRP Advisory Group, UK professional services firm specialising in restructuring advisory. Raising £80m (£20m primary). Expected market cap £190m. Compound annual growth of 16.4 per cent. in revenue and 10.9 per cent. in operating profit since the beginning of FY17.o Strong average EBITDA margins of 51 per cent. over FY17 to FY19, and consistently strong cash conversion
Companies: XPD PHD OCI HAYD UEX ITX ONC PHE STA
Inspecs, a UK designer, manufacturer and distributor of eyewear frames to global retail chains announces its intention to IPO onto AIM raising £94m with a market cap of £138m. Admission expected 27th February. FY Dec 2018 numbers show revenue of $57m and underlying EBITDA of $11m
Companies: IHC TRCS IMMO PHD STAF DMTR TOU OSI IPEL BBB
Shares of cloud communications company Twilio fell as much as 17% on Wednesday after the company gave lower-than expected quarterly earnings and revenue guidance. Earnings: Excluding certain items, 3 cents per share, vs. 1 cent per share as expected by analysts, according to Refinitiv. Revenue: $295.1 million, vs. $287.8 million as expected by analysts, according to Refinitiv. Twilio's revenue grew 75% in the fiscal third quarter, which ended on September 30, according to a statement.
Companies: CALL PHD KNOS ESYS
SAP has struck a three-year agreement with Microsoft to support its customers’ migration into cloud-based systems. The partnership, called "Embrace", will help clients to run operations hosted at remote servers supported by SAP's flagship S/4HANA database. Under the agreement, SAP's cloud platform services will be bundled with SAP systems and sold through Microsoft's distribution channels. In the past two months, Google has revealed new Pixel phones, Microsoft has launched Surface tablets and laptops, Facebook has introduced a new smart display called Portal along with Oculus VR headsets and Amazon has rolled out a plethora of gadgets that work with its voice assistant, Alexa. We look into why Big Tech is so focused on hardware given their software pedigrees.
AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019. VAALCO Energy, Inc. (NYSE: EGY), an independent energy com pany focused on developm ent and production assets in West Africa, today announces its formal intention to seek a Standard Listing on the Main Market of London Stock Exchange ("LSE"), to complement its existing Listing on the New York Stock Exchange. Kaspi.kz, the largest Paym ents, Marketplace and Fintech Ecosystem in Kazakhstan w ith a leading m arket share in each of its key products and services, announces today the expected publication of a registration document that has been submitted for approval to the FCA and its potential intention, subject to market conditions, to undertake an initial public offering. Registration document approved for Helios Towers. The Group provides essential network services, flexible infrastructure solutions and reliable power supply to mobile network operators in five African growth economies. Revenue increased 7 per cent. year-on-year to US$191m (H1 2018: US$178m), with Adjusted EBITDA up 15 per cent. year-on-year at US$99m (H1 2018: US$86m) for the six months ended 30 June 2019.
Companies: NAK GFIN CCS PHD MED OSI DDDD MWE THRU
Research Tree provides access to ongoing research coverage, media content and regulatory news on Proactis Holdings Plc.
We currently have 100 research reports from 6
LoopUp has announced a very strong H1 period, in line with the previous trading update and reflecting a number of months of exceptional performance. This is allowing the business to invest in the major identified new opportunity, to provide telephony within Microsoft Teams, where the early signs are extremely positive. We look forward to further detail on the Teams pipeline and sales levels over time.
Companies: LoopUp Group plc
ZOO has provided a short trading update to accompany its AGM which will be held later today. The business is performing well…double-digit revenue growth y/y across H1 is clearly a strong result given the market disruption, and is tracking very well towards our full-year figure. We make no changes to estimates (which we reinstated in July) but will consider revisiting them at the time of the H1 results in early November.
Companies: ZOO Digital Group Plc
Covid has accelerated the digitisation of all things physical. No more so than in the €10 trillion global construction industry, which some experts reckon has 5 years of catching up to do. A non-insignificant task (eg Crossrail & HS2) that could take decades to play out, but equally realise 100s of £bns of cost, time & productivity savings annually. The €8bn BuildTech sector (10%+ CAGR – see below) is at the heart of this transformation. Providing the glue & ‘digital twins’ that bind all the inter-connected ‘property lifecycle’ parts together – eg CAD/CAM (design), project mgt, visualisation, AI, asset maintenance (operate) and BIM (Building Info Modelling).
Companies: Eleco Plc
As flagged in the July trading update, the Eleco group (formerly Elecosoft) has delivered impressive first half financials in the face of the global pandemic. However, the results are somewhat overshadowed by the retirement of Executive Chairman, John Ketteley, after 23 years in the role. The COO, Jonathan Hunter, takes over as CEO and the Deputy Chairman, Serena Lang, steps up to Chairman. Both are very experienced and offer safe hands to guide Eleco forward through the unprecedented conditions of COVID-19. In the early stages of the pandemic, the group demonstrated its resilience as H1 revenue slipped just 4% YoY with 57% revenue being recurring. Moreover, benefiting from reduced cost of travel and marketing, H1 adj. PBT rose 12% YoY to £2.2m. The profit uplift was matched by strong cashflow, improving net cash from £1.1m at YE to a very healthy £4.4m at the end of June. Forecasts remain under review due to uncertainty in the COVID-19 environment, but Eleco continues to be well positioned – not just to weather the storm of pandemic, but to deliver a strong financial performance across the full year.
Actively managing the business successfully through the consequences of COVID-19, Ideagen finals to end April are in line with the May trading update and unchanged expectations: EBITDA of £18.5m as expected, revenue of £56.6m (£56.0mE originally), and robust free cash flow of £10.1m robust even after COVID restructuring costs, leading y/e net debt of £16.8m (0.9x net debt/EBITDA), as expected. Rapid and effective action to accommodate the consequences of lockdown maintained the quality of business, still achieving 5% organic growth, on top of three acquisitions in the period, to deliver 21% headline revenue growth. Once again, expectations were exceeded for recurring revenue, increasing from 74% at 1H20 to 76% (FY19: 67%): target recurring revenue had already been lifted from 75 to 80% by FY22 – and the horizon is now extended to 85% by FY23. FY19 acquisitions are all now integrated in line with the 72-step efficient process; organic growth is maintained even during a pandemic; trading since year end is robust; and the acquisition pipeline still remains active. With the success of the formula evident in its execution, and the benefit of future acquisitions unmodelled, we lift our target price to 235p (220p).
Companies: Ideagen Plc
LoopUp recently unveiled a major extension to its ambitions – the group is aiming to become a leading global provider of telephony “inside” Microsoft’s Teams product. The opportunity is clear and growing, as enterprise customers look to use Teams for “normal” external phone calls, and LoopUp seems well placed to deliver a differentiated offering using its existing infrastructure and knowhow. In this document we provide an overview of the new platform and explain its strategic significance.
The launch of LiveData Migrator with AWS represents another big step forward for WANdisco. Aside from diversifying the sales base, it suggests that the company’s technology is becoming the established way to migrate large, active datasets to the cloud. Disappointing H1 financials and a delay in the ramp of Azure revenue from Q3 to Q4 leads us to cut our FY20 forecasts. However, Q4 should see a big uplift in financial performance and our newly introduced FY21 forecasts see sales rising to $37m.
Companies: WANdisco Plc
Ideagen is a leading supplier of information management software, specialising in Integrated Risk Management (IRM) solutions to highly regulated industries. Consistently recognised in the Gartner Magic Quadrant since 2016 for its solution set, Ideagen has developed a best-of-breed IRM suite through a blend of internally driven R&D and strategic acquisitions, earning the group significant presence in its core markets. Our mantra remains that the three certainties in life are death, taxes and regulatory compliance – Ideagen is positioned to grow from strength to strength, as organisations worldwide are faced with increasingly demanding regulatory standards, and the requirement to provide a referenceable trail of accountability. As the group embarks on its twelfth consecutive year of growth, coupled with the potential upside of inevitable acquisitions, we believe Ideagen is poised for ongoing acceleration into the coming years.
Salarius Ltd. (91.7% owned by TEK) has signed a distribution agreement with FXM Ingredients Inc. to distribute MicroSalt® in Mexico and Latin America.
Companies: Tekcapital Plc
The headline numbers in this morning's results are not new news, having already been flagged to the market in the company's update on August 13th. Rather, the new news is (1) cost-savings in excess of £1m, (2) post-period end contract wins which add around £2m to FY20E likely revenues, (3) breaking of some H1 logjams due to Covid, with key design reviews passed for General Dynamics and substantial invoices raised and paid. £2m net cash on the balance sheet previously flagged is confirmed, and the Absolute Data Group (ADG) acquisition has integrated well. With effective conversion of the Letter of Intent relating to a Middle East customer during H1, and additional orders from other clients, the company's expectation of uplift in H2 looks to be well underpinned. Clearly the company rolled with the Covid punches in the first half; however the £1m annualised savings look to be really helpful in supporting FY21E financials and the order book remains healthy (+9% since the year end). Frustratingly, the Major Programme previously announced in PEN's pipeline remains a waiting game; however, we would still see conversion as transformational.
Companies: Pennant International Group Plc
Renalytix has officially commercially launched the KidneyIntelX testing platform with its launch partner Mount Sinai. The test is now fully integrated into the Mount Sinai health system, and goes beyond mere patient testing into a holistic approach to CKD patient support with Mount Sinai’s care delivery, physician education and support and billing pathways. This is a pivotal milestone for Renalytix triggering first commercial testing revenues, and was achieved in less than two years since Renalytix first IPOd in November 2018. It is estimated there are approx. 66,000 Diabetic kidney disease patients at the Mount Sinai health system, representing a significant initial addressable market opportunity. We continue to expect the launch and similar integrations of the KidneyIntelX platform into two further health care systems in FY’21. Simultaneously, Renalytix also announced agreements with LabCorp and an unnamed national medical logistics provider to use additional service centres to support the launch with the collection of blood samples at centres close to home or by primary physicians within the Mount Sinai system. Given the ongoing Covid-19 pandemic and the impact on physician visits, we believe this is beneficial and aids the use of KidneyIntelX to remotely monitor patients. This also provides a logistics framework to scale this process across multiple territories in the US.
Companies: Renalytix AI Plc
Tern plc* (TERN.L, 8.0p/£24.1m) | Corero Network Security (CNS.L, 8.25p/£40.8m) | Eagle Eye Solutions Group plc (EYE.L, 288p/£86.9m)
Companies: TERN CNS EYE
PTY's results this morning are in line with indications given by the company on July 20th, when the company announced anticipated gross revenues of £30m and a “modest” adjusted pre-tax profit, in line with the adjusted PBTA of £0.06m published this morning, and a significantly reduced reported pre-tax loss. As previously announced, the company succeeded in moving from net debt (£1.2m pre lease liabilities) to net cash, £0.7m, at the half year end. Cost-savings have been significant at £4.2m gross, £2.4m net, opening the door to the significant transformation undertaken by the company and creating a new and robust underlying platform which has been stress-tested by Covid. As expected, net revenues (net fee income) have reduced on the back of the Scottish Government contract exit, which was low-margin and in run-off. The company expects to achieve a full-year profit equivalent to >£0.1m PBTA posted in FY2019A and a notable feature of the results is that no more non-underlying costs are expected going forward, leading to prospective upside both adjusted and unadjusted.
Companies: Parity Group Plc
Crimson Tide has reported a strong set of H1 results evidencing very strong sales momentum backed by long-term contracts and cash flow. H1 sales grew by 40% and EPS by 154%. Net cash has improved to £0.8m at June 2020 from nil at December 2019. The strategic focus on transportation and supermarkets is working well, partnerships are improving routes to market, and there is growing traction from investments in innovation. We have left our forecasts unchanged for now, but recognise positive pressure and have upgraded our target price from 3.1p to 4.3p. We reiterate our view that Crimson Tide’s valuation will be dictated by its ability to convert the significant opportunity rather than short-term metrics. H1 results show the group is nicely on track to do exactly that.
Companies: Crimson Tide Plc
Location Sciences Group PLC (LON:LSAI) is a high growth technology company and a global leader in location verification. The company recently reported results for the first half (H1) of 2020. These were in line with the trading update issued in July, with revenues up 1% (or +43% including securitis
Companies: Location Sciences Group Plc